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Abstract
Background and purpose: Coronavirus disease 2019 (COVID-19) is associated with a small but clinically significant
risk of stroke, the cause of which is frequently cryptogenic. In a large multinational cohort of consecutive COVID-19
patients with stroke, we evaluated clinical predictors of cryptogenic stroke, short-term functional outcomes and in-
hospital mortality among patients according to stroke etiology.
Methods: We explored clinical characteristics and short-term outcomes of consecutively evaluated patients 18 years
of age or older with acute ischemic stroke (AIS) and laboratory-confirmed COVID-19 from 31 hospitals in 4 countries
(3/1/20–6/16/20).
Results: Of the 14.483 laboratory-confirmed patients with COVID-19, 156 (1.1%) were diagnosed with AIS. Sixty-one
(39.4%) were female, 84 (67.2%) white, and 88 (61.5%) were between 60 and 79 years of age. The most frequently
reported etiology of AIS was cryptogenic (55/129, 42.6%), which was associated with significantly higher white
blood cell count, c-reactive protein, and D-dimer levels than non-cryptogenic AIS patients (p</=0.05 for all
comparisons). In a multivariable backward stepwise regression model estimating the odds of in-hospital mortality,
cryptogenic stroke mechanism was associated with a fivefold greater odds in-hospital mortality than strokes due to
any other mechanism (adjusted OR 5.16, 95%CI 1.41–18.87, p = 0.01). In that model, older age (aOR 2.05 per decade,
95%CI 1.35–3.11, p < 0.01) and higher baseline NIHSS (aOR 1.12, 95%CI 1.02–1.21, p = 0.01) were also independently
predictive of mortality.
Conclusions: Our findings suggest that cryptogenic stroke among COVID-19 patients carries a significant risk of
early mortality.
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Introduction
Since December 2019, coronavirus disease 2019
(COVID-19), caused by severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), has become a pan-
demic infecting more than 81 million people worldwide
and causing more than 1.700.000 deaths [1]. Although
respiratory symptoms are most commonly reported,
neurological symptoms are increasingly recognized, and
range from 36 to 56% according to large series of hospi-
talized patients [2–4], with a small but clinically signifi-
cant risk of acute ischemic stroke (AIS) [5–7].
Potential mechanisms of SARS-CoV-2-associated
stroke have been described and include a prothrombotic
state [3, 8, 9], hyperinflammatory response, cardiomyop-
athy and endothelial injury from direct viral invasion
[10–12]. Among hospitalized patients, COVID-19 has
been recognized as an independent predictor of AIS and
is associated with poor outcomes with considerable early
mortality in small observational cohorts [13, 14]. The
aim of this study was to characterize clinical, radio-
graphic, and laboratory predictors of cryptogenic stroke
using a multinational registry, and to evaluate short-
term outcomes of patients with SARS-CoV-2 associated
stroke according to traditional stroke mechanisms.
Methods
Study design and participants
Between 3/1/2020 and 6/16/2020, we pooled consecutive
patients >/= 18 years of age hospitalized or evaluated in
the emergency department (ED) with AIS and confirmed
diagnosis of COVID-19 by oropharyngeal polymerase
chain reaction (PCR) or IgG and/or IgM antibody in
sera, using local commercial assays, in 31 hospitals
across 4 countries. A more detailed summary of the
Methods has been previously described [7]. Informed
consent was waived by the local institutional review
board at each participating center. No sample size calcu-
lations were made for this study as analyses were ex-
ploratory and hypothesis-generating. The results of this
investigation are reported in accordance with the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) statement.
Data collection
Demographic, clinical, and laboratory findings (including
method of COVID-19 diagnosis), as well as stroke treat-
ment (including intravenous thrombolysis, endovascular
thrombectomy, and antithrombotic therapy), and short-
term functional outcomes at time of discharge were col-
lected. Stroke etiology was determined by local site in-
vestigators (vascular neurologists) using a modified Trial
of ORG 10172 in Acute Stroke Treatment (TOAST)
classification [15]. Cryptogenic stroke was defined as
stroke of undetermined etiology after exclusion of
cardiac sources of embolism, large artery atherosclerotic
stenosis, and small vessel disease. Patients with incom-
plete workup were also considered to have cryptogenic
infarcts. Pre-morbid and discharge functional status
were determined using the modified Rankin Scale [16,
17]. Neuroimaging was performed at the discretion of
the treating physician and radiographic findings (e.g., lo-
cation of infarction, presence of an intracranial occlu-
sion) were reported by local site investigators. Each
center reported their in-hospital mortality rate among
all COVID-19 patients throughout the study period.
Data were recorded on a HIPAA-compliant, online
registry, as previously described [18]. Data elements with
< 50% completion rate (e.g., erythrocyte sedimentation
rate) were not reported in order to limit selection bias.
Outcome measures
The primary study outcome was the diagnosis of a
cryptogenic (undetermined) mechanism of stroke. Sec-
ondary outcomes included discharge disability (accord-
ing to mRS), discharge disposition, and in-hospital
mortality among patients with COVID-19 when strati-
fied by cause of acute ischemic stroke. To maximize spe-
cificity of findings, patients with more than one possible
stroke mechanism (n = 9) were excluded from compara-
tive analyses involving stroke mechanisms.
Statistical analysis
Normality of continuous data was assessed histographi-
cally and confirmed using the Shapiro-Wilk test. Non-
normally distributed continuous variables are summa-
rized as medians with interquartile range. Categorical
variables are presented as frequencies (%). Descriptive
statistics were used to compare groups, with the χ2 test
for discrete variables (or Fisher’s exact test when cell
counts were 5 or less), and the Wilcoxon Rank-sum test
or Kruskal-Wallis equality of populations rank test for
non-normally distributed continuous variables, as appro-
priate. Bivariate analyses were performed to associate
baseline variables with the occurrence of endpoints.
Backward stepwise logistic regression was performed to
estimate the association between clinical, laboratory, and
radiographic findings with the primary and secondary
outcomes. Estimates of association are presented as odds
ratios (OR) and respective 95% confidence intervals (CI),
with adjustment for all variables significant to p < 0.2 on
the respective bivariate analysis. Variables were elimi-
nated from each adjusted model if they were no longer
significant to p < 0.2. All adjusted regression models
were clustered by site. Using the remaining variables
from the final backward stepwise regression model for
mortality, we created a simple index assigning 1-point to
each variable (age, male sex, history of diabetes, NIHSS,
and cryptogenic stroke; Supplementary Table 1). In
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order to reduce overfitting, NIHSS was stratified such
that one point was assigned for values ≥10 and age
stratified such that one point was assigned if the patient
were ≥ 60 years old based on visual association of these
thresholds with respect to associated risk of mortality
(Supplementary Figs. 1 and 2). The mortality rate of the
cohort was assessed for each point value. A receiver op-
erating characteristic curve was generated to test the as-
sociation between the mortality score and in-hospital
mortality. Model performance was assessed using the c-
statistic with 95% CI. The statistical significance level of
all tests was defined as a p-value ≤0.05. As this was an
exploratory study, no adjustments were made for mul-
tiple comparisons. P-values are provided for conven-
tional purposes only and should be interpreted with
caution. All tests were performed at the two-sided level
using STATA (College Station, TX) version 15.0. Miss-
ing data were not imputed. Fully de-identified data can




Of the 14,483 laboratory-confirmed SARS-CoV-2 pa-
tients, 156 (1.1%) were diagnosed with a clinical and/or
radiographic acute ischemic stroke. Antecedent systemic
symptoms were reported with variable frequency but in-
cluded fever in 69/134 patients (51%), 77/133 (58%) with
cough, 60/128 (47%) dyspnea, 21/112 (19%) chest pain,
18/107 (17%) myalgias, 12/110 (11%) headache, and <
10% with symptoms of congestion, dizziness, odynopha-
gia, hyposmia, or hypogeusia. Among stroke patients,
61/155 (39.4%) were female, 84/125 (67.2%) White, and
more than half of patients (n = 88/143, 61.5%) were be-
tween 60 and 79 years of age. Seventeen of 145 patients
(11.7%) received intravenous thrombolysis, and 14/156
(9.0%) were reported to experience any intracerebral
hemorrhage—1 patient experienced a NIHSS worsening
of 4 points attributed to a parenchymal hematoma, how-
ever this patient did not receive intravenous thromboly-
sis or thrombectomy.
The etiology of stroke was reported in 129 of 156
stroke patients (82.7%), with cryptogenic being com-
monly reported (n = 55, 42.6%). Compared to patients
with any other defined stroke mechanism (or multiple
possible mechanisms), patients with cryptogenic stroke
were more frequently Hispanic (51.0% vs. 33.3%, p =
0.05), had less atrial fibrillation (p < 0.01) and congestive
heart failure (p = 0.05; Table 1).
There was no difference with respect to age, sex, race,
or history of pre-morbid disability among patients with
cryptogenic versus known stroke mechanisms.
In a separate analysis of 11 sites included in this study
which submitted data of ischemic stroke patients
irrespective of SARS- CoV-2 infection during a similar
period the year prior (3/1/19–05/31/19), the prevalence
of cryptogenic (unspecified or undetermined) stroke was
19.7% (260/1319 patients) [19]. Using a two-sample test
of proportions, the rate of cryptogenic stroke was signifi-
cantly higher in this population of COVID-19-associated
stroke (42.6% vs. 19.6%, p < 0.001). Furthermore, the re-
ported in-hospital mortality rate among these patients
was also significantly greater than in this historic control
group (38.1% vs. 7.8%, p < 0.001).
On admission, neurological deficits according to base-
line NIHSS were generally moderate-to-severe among all
patients, with more severe deficits noted in patients with
strokes due to a cryptogenic mechanism, cardioembo-
lism, or other identifiable mechanism, compared to pa-
tients with large or small vessel disease (p = 0.02;
Table 2).
Compared to non-cryptogenic stroke patients, those
with cryptogenic strokes had no difference in baseline
NIHSS (p = 0.53). Patients with cardioembolic stroke
had more frequently identified intracranial arterial oc-
clusions and cortical involvement compared to other
stroke mechanisms (p < 0.05 for both findings), followed
by cryptogenic stroke. Admission white blood cell count,
C-reactive protein and D-dimer levels were significantly
greater for patients with cryptogenic stroke when com-
pared to all other stroke groups, and after multivariable
regression with adjustment for all candidate variables
significant to p < 0.2 (Hispanic ethnicity, congestive heart
failure, cortical infarction, white blood cell count and D-
dimer), only congestive heart failure was statistically sig-
nificantly and inversely associated with cryptogenic
stroke mechanism (p < 0.01; Table 3).
Patients with strokes due to cardioembolism and a
cryptogenic mechanism had a significantly higher risk of
any hemorrhagic transformation when compared to
strokes of all other classifications, although event rates
for strokes due to ‘other’ causes and small vessel disease
were low (p = 0.05; Table 4). Patients with cryptogenic
stroke were non-significantly more likely to be dis-
charged with greater disability than strokes of other
mechanisms (p = 0.07), despite having a similar pre-
morbid functional status. Furthermore, cryptogenic
stroke patients had a significantly higher risk of in-
hospital mortality when compared to strokes of all other
mechanisms (OR 2.27, 95%CI 1.01–5.08, p = 0.05). In the
backward stepwise regression model for in-hospital mor-
tality, cryptogenic stroke remained independently associ-
ated with in-hospital mortality (aOR 5.16, 95%CI 1.41–
18.87, p = 0.01). In that model, older age (aOR 2.05 per
decade, 95%CI 1.35–3.11, p < 0.01), higher baseline
NIHSS (aOR 1.12, 95%CI 1.02–1.21, p = 0.01), and his-
tory of diabetes (aOR 6.89, 95%CI 1.02–46.76, p = 0.05)
remained independently associated with mortality,
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whereas male sex was slightly but non-significantly asso-
ciated with mortality (aOR 2.39, 95%CI 0.69–8.28, p =
0.17; supplementary Table 1). Neither intravenous
thrombolysis (OR 0.82, 95%CI 0.27–2.52, p = 0.73) nor
thrombectomy (OR 0.97, 95%CI 0.40–2.34, p = 0.95)
were associated with mortality in univariate modeling. A
simple risk score was derived from the five variables
from the backward stepwise regression model by assign-
ing 1-point each in order to estimate the risk of in-
hospital mortality. Additional points showed an



















Age, no. (%) 0.10 0.97
< 30 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
30–39 3 (2.5) 1 (1.8) 2 (5.7) 0 (0) 0 (0) 2 (18.2
40–49 12 (10.0) 6 (10.9) 2 (5.7) 0 (0) 0 (0) 4 (36.4)
50–59 15 (12.5) 6 (10.9) 5 (14.3) 2 (13.3) 0 (0) 2 (18.2)
60–69 36 (30.0) 19 (34.6) 8 (22.9) 6 (40.0) 1 (25.0) 2 (18.2)
70–79 37 (30.8) 16 (29.1) 13 (37.1) 5 (33.3) 2 (50.0) 1 (9.1)
80–89 12 (10.0) 5 (9.1) 4 (11.4) 2 (13.3) 1 (25.0) 0 (0)
> 89 5 (4.2) 2 (3.6) 3 (8.6) 0 (0) 0 (0) 0 (0)
Sex, no. female (%) 61/155 (39.4) 19/55 (34.6) 15/35 (42.9) 5/14 (35.7) 0/4 (0) 8/11 (72.7) 0.08 0.45
Race, no. (%) 0.52 > 0.9
White 84/125 (67.2) 31/45 (68.9) 21/28 (75.0) 9/12 (75.0) 2/3 (66.7) 5/10 (50.0)
Black 35/125 (28.0) 12/45 (26.7) 7/28 (25.0) 2/12 (16.7) 1/3 (33.3) 4/10 (40.0)
Asian 2/125 (1.6) 1/45 (2.2) 0/28 (0) 0/12 (0) 0/3 (0) 0/10 (0)
More than one race 2/125 (1.6) 1/45 (2.2) 0/28 (0) 1/12 (8.3) 0/3 (0) 0/10 (0)
Other 2/125 (1.6) 0/45 (0) 0/28 (0) 0/12 (0) 0/3 (0) 1/10 (0)
Hispanic ethnicity, no. (%) 58/140 (41.4) 25/49 (51.0) 10/33 (30.3) 4/12 (33.3) 4/4 (100) 10/11 (90.9) 0.02 0.05
Diagnosis of COVID-19 d, no. (%) 0.11 0.83
Nasopharyngeal PCR 153 (98.1) 55/55 (100) 35/35 (100) 15/15 (100) 4/4 (100) 10/11 (90.9)
Serum IgM and/or IgG 6 (3.8) 2/55 (3.6) 3/35 (8.6) 0/15 (0) 1/4 (25.0) 1/11 (9.1)
Known COVID-19 exposure, no. (%) 19 (12.2) 8/55 (14.6) 5/35 (14.3) 1/15 (6.7) 0/4 (0) 2/11 (18.2) 0.82 0.69
Medical history, no. (%)
Hypertension 111/154 (72.1) 38/53 (71.7) 26/35 (74.3) 12/15 (80.0) 4/4 (100) 4/11 (36.4) 0.10 0.87
Diabetes mellitus 65/152 (42.8) 22/51 (43.1) 13/35 (37.1) 5/15 (33.3) 2/4 (50.0) 7/11 (63.6) 0.56 0.87
Dyslipidemia 58/142 (40.9) 18/53 (34.0) 17/35 (48.9) 7/15 (46.7) 3/4 (75.0) 0/11 (0) 0.01 0.33
Atrial fibrillation 22/148 (14.9) 0/52 (0) 16/35 (45.7) 0/15 (0) 0/4 (0) 0/11 (0) < 0.01 < 0.01
Congestive heart failure 27/154 (17.5) 5/53 (9.4) 9/35 (25.7) 4/15 (26.7) 0/4 (0) 1/11 (9.1) 0.17 0.05
Active tobacco use 15/145 (10.3) 4/52 (7.7) 5/33 (15.2) 0/15 (0) 1/4 (25.0) 0/11 (0) 0.21 0.68
Prior stroke 15/140 (10.7) 6/42 (12.5) 2/33 (6.1) 0/13 (0) 0/4 (0) 0/11 (0) 0.59 0.33
Chronic renal insufficiency
(stage III/IV or dialysis-dependent)
16/144 (11.1) 3/47 (6.4) 1/33 (3.0) 2/13 (15.4) 0/4 (0) 3/11 (27.3) 0.11 0.49
Chronic obstructive pulmonary
disease and/or asthma
11/135 (8.2) 2/48 (4.2) 3/33 (9.1) 0/13 (0) 1/4 (25.0) 0/11 (0) 0.28 0.24
Cancer 8/134 (6.0) 4/47 (8.5) 1/33 (2.9) 0/13 (0) 1/4 (25.0) 0/11 (0) 0.29 0.35













Of the 11 patients with ‘Other’ etiologies, 2 had hypercoagulable states due to malignancy, 1 with hypercoagulability on laboratory testing unrelated to
malignancy, 2 with arterial dissection, 1 with vasculitis due to mucormycosis, 3 with radiographic findings of posterior reversible encephalopathy with infarction,
and 2 with etiologies not otherwise specified
a Acute ischemic stroke includes suspected or radiographically-confirmed cases, and in patients with multiple possible stroke mechanisms (n = 9). Patients
with multiple stroke mechanisms were not included in the subsequent columns in order to minimize heterogeneity
b P-values indicate categorical comparisons between all stroke subtypes
c P-values indicate comparisons between cryptogenic and non-cryptogenic stroke subtypes (including strokes due to multiple possible etiologies)
d 3 patients with an acute ischemic stroke were diagnosed with COVID-19 using both serum antibodies and nasopharyngeal PCR. COVID-19 denotes
coronavirus disease 2019, PCR polymerase chain reaction
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incrementally greater probability of mortality (Fig. 1),
with the total score having a strong discriminatory
power to predict in-hospital mortality (area under the
curve 0.79, 95%CI 0.70–0.88). Three or more points in-
dicated an 88.9% sensitivity and 53.0% specificity for the
outcome of in-hospital mortality.



















Clinical and radiographic findings













Head CT performed, no. (%) 135/151 (89.4) 48/55 (87.3) 34/35 (97.1) 14/15 (93.3) 4/4 (100) 10/11
(90.9)
0.56 0.25
First CT indicating acute stroke, no. (%) 76/132 (57.6) 33/48 (68.8) 21/34 (61.8) 10/14 (71.4) 0/4 (0) 4/10 (40.0) 0.04 0.10
CT angiogram performed, no. (%) 99/151 (65.6) 36/55 (65.5) 23/35 (65.7) 14/15 (93.3) 4/4 (100) 10/11
(90.9)
0.07 0.36
Intracranial occlusion, no. (%) 53/107 (49.5) 17/37 (46.0) 17/24 (70.8) 6/14 (42.9) 0/4 (0) 3/10 (30.0) 0.04 0.70
MRI brain performed, no. (%) 55/151 (36.4) 21/55 (38.2) 11/35 (31.4) 5/15 (33.3) 1/4 (25.0) 8/11 (72.7) 0.17 > 0.9
MRI evidence of acute stroke, no. (%) 45/55 (81.8) 15/21 (71.4) 9/11 (81.8) 5/5 (100) 1/1 (100) 8/8 (100) 0.42 0.05
CT or MRI location of infarction, no. (%)
Cortical 81/101 (80.2) 29/39 (74.4) 26/28 (92.9) 11/12 (91.7) 0/2 (0) 10/10
(100)
< 0.01 0.09
Subcortical supratentorial 54/101 (53.5) 18/39 (46.2) 15/28 (53.6) 5/12 (41.7) 2/2 (0) 7/10 (70.0) 0.43 0.38
Infratentorial 12/101 (11.9) 7/39 (18.0) 0/28 (0) 1/12 (8.3) 0/2 (0) 1/10 (10.0) 0.12 0.11
Laboratory testing



















































































Intravenous thrombolysis, no. (%) 17/145 (11.7) 4/54 (7.4) 7/35 (20.0) 3/15 (20.0) 0/4 (0) 2/11 (18.2) 0.31 0.12
Endovascular treatment, no. (%) 33/114 (29.0) 8/42 (19.1) 14/26 (53.9) 4/10 (40.0) 0/3 (0) 2/7 (28.9) 0.03 0.03
Endovascular treatment d, no. (%) 33/53 (62.3) 8/17 (47.1) 14/17 (82.4) 4/6 (66.7) n/a 2/3 (66.7) 0.18 0.11
Acute antithrombotic treatment e, no. (%) 0.01 0.17
Single or dual antiplatelet therapy 66/108 (61.1) 31/43 (72.1) 13/30 (43.3) 12/12 (100) 2/3 (66.7) 6/10 (60.0)
Therapeutic anticoagulation f 22/108 (20.4) 5/43 (11.6) 11/30 (36.7) 0/12 (0) 1/3 (33.3) 1/10 (10.0)
None 20/108 (18.5) 7/43 (16.3) 6/30 (20.0) 0/12 (0) 0/3 (0) 3/10 (30.0)
a Acute ischemic stroke includes suspected or radiographically-confirmed cases, and in patients with multiple possible stroke mechanisms (n = 9). Patients
with multiple stroke mechanisms were not included in the subsequent columns in order to minimize heterogeneity
b P-values indicate categorical comparisons between all stroke subtypes
c P-values indicate comparisons between cryptogenic and non-cryptogenic stroke subtypes (including strokes due to multiple possible etiologies)
d Analysis limited to patients with any intracranial occlusion on vascular imaging
e Acute antithrombotic treatment was defined as use of an antithrombotic within 24 h of ischemic stroke diagnosis, or between 24 and 48 h of ischemic
stroke diagnosis in patients who received intravenous thrombolysis
f One patient with a stroke due to multiple etiologies was treated with combination antiplatelet (single or dual) with therapeutic anticoagulation
NIHSS Denotes National Institutes of Health Stroke Scale, IQR Interquartile range, CT Computed tomography, MRI Magnetic resonance imaging, HI-1 Denotes
hemorrhagic infarction grade 1 (petechial hemorrhage), HI-2 Hemorrhagic infarction grade 1 (confluent petechiae), PH-1 Parenchymal hematoma grade 1
(confluent hemorrhage within < 30% of infarct bed), PH-2 Parenchymal hematoma grade 2 (confluent hemorrhage within > 30% of infarct bed and having
mass effect), ICU intensive care unit and mRS modified Rankin Scale
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Discussion
In this observational cohort of more than 14,000
COVID-19 patients treated at 31 hospitals in 4 coun-
tries, we found a high proportion of strokes among pa-
tients with COVID-19 were attributed to a cryptogenic
mechanism (42%). This finding is concordant with the
growing literature indicating a high prevalence of crypto-
genic stroke in COVID-19, [6, 13, 20, 21] with increasing
data suggesting the novel human coronavirus may be a
novel stroke mechanism. In this study, a cryptogenic
stroke diagnosis was made at the judgment of the treat-
ing vascular neurologist and was inclusive of strokes
with incomplete workup. Use of more stringent trial cri-
teria for “cryptogenic stroke” (which requires thorough
evaluation for cardiac and vascular causes of cerebral in-
farction) in the present study would certainly strengthen
the observed association implicating COVID-19 as a po-
tentially unique stroke mechanism. However, we did not
centrally adjudicate vascular, echocardiographic, or par-
enchymal imaging in order to confirm the diagnosis of
cryptogenic infarction. Our determination of cryptogenic
stroke is congruent with many published reports which
did not report a detailed methodology for determination
of cryptogenic mechanism, [22] did not require intracra-
nial vascular imaging, [23] or included patients for
whom workup could not be completed [20]. Therefore,
we do not believe the clinical determination of crypto-
genic stroke to be a significant limitation of this analysis.
Table 3 Multivariable logistic regression model evaluating predictors for cryptogenic stroke in Covid-19 patients
Variable Univariate analysis Multivariable analysis
OR (95% CI) p-value OR (95% CI) p-value
Age, per decade 0.98 (0.75–1.27) 0.86
Male sex 1.32 (0.64–2.73) 0.45
White race 1.06 (0.46–2.42) > 0.9
Hispanic ethnicity 1.44 (0.99–2.10) 0.05 Dropped from model due to non-
significance
Medical history
Hypertension 0.94 (0.43–2.06) 0.87
Diabetes mellitus 0.94 (0.46–1.93) 0.87
Dyslipidemia 0.70 (0.33–1.45) 0.34
Congestive heart failure 0.35 (0.12–1.02) 0.05 0.15 (0.05–0.44) < 0.01
Active tobacco use 0.76 (0.21–2.75) 0.68
Prior stroke 1.86 (0.53–6.47) 0.33
Chronic renal insufficiency (stage III/IV or dialysis-
dependent)
0.61 (0.15–2.50) 0.50
Chronic obstructive pulmonary disease and/or asthma 0.39 (0.08–1.97) 0.26
Cancer 2.08 (0.44–9.74) 0.35
Baseline NIHSS a 0.003 (−0.006–0.013) 0.49
Imaging
Cortical infarction 0.40 (0.14–1.16) 0.09 Dropped from model due to non-
significance
Large vessel occlusion 0.95 (0.37–1.95) 0.70
Laboratory data a
Admission WBC (× 1000/mL) 0.02 (0.002–0.04) 0.03 Dropped from model due to non-
significance
Admission lymphocyte count (× 1000/mL) 0.0001 (−0.12–0.12) > 0.9
Admission platelet count (× 1000/mL) 0.0004 (−0.0003–
0.001)
0.22
D-dimer (per mcg/mL) 0.009 (0.002–0.017) 0.02 1.73 (0.98–3.04) 0.06
C-reactive protein (per mg/dL) 0.001 (−0.0008–0.003) 0.23
Variables were entered into the multivariable model if they were significant to p < 0.2 in univariate regression (Hispanic ethnicity, congestive heart failure, cortical
infarction, elevated d-dimer, elevated admission white blood cell count). Variables were retained if they remained significant to p < 0.2. Laboratory values indicate
serologic studies collected closest to the time of stroke onset, unless otherwise noted
a Variables in which β with 95% confidence interval were used to estimate the effect on the outcome of cryptogenic stroke in univariate analysis. If included in
the multivariable model, this effect is displayed as an odds ratio with 95% confidence interval. Multivariable regression model was clustered by site
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Perhaps the most important observation in this co-
hort is the relationship between stroke mechanism
and in-hospital mortality. When compared to other
discharge dispositions, death was the most common
singular discharge disposition in this cohort of stroke
patients. When death was evaluated as a bivariate
outcome, having a cryptogenic stroke mechanism was
significantly and independently predictive of in-
hospital mortality. The high mortality rate is consist-
ent with other cohorts [6, 13, 20] and adds to the re-
sults of one recent systematic review and meta-
analysis demonstrating a 5-fold increase in in-hospital
mortality among COVID-19 stroke patients when
compared to their contemporary noninfected or his-
torical controls [21]. It should be noted that patients
in the present cohort contributed to this meta-
analysis by Katsanos and colleagues; however the pa-
tients in the present study did not contribute to the
comparison of in-hospital mortality rates among
COVID-19 stroke patients and COVID-19-negative
controls.
In our study, admission white blood cell count, c-
reactive protein, and D-dimer levels were significantly
higher for patients later diagnosed with cryptogenic





















17/98 (17.4) 6/42 (14.3) 3/26 (11.5) 0/8 (0) 0/4 (0) 4/7
(57.1)
0.05 0.55
Grade of hemorrhage > 0.9 0.82
HI-1 7/17 (41.2) 3/6 (50.0) 1/3 (33.3) n/a n/a 2/4
(50.0)
HI-2 2/17 (11.8) 1/6 (16.7) 0/3 (0) n/a n/a 1/4
(25.0)
PH-1 4/17 (23.5) 1/6 (16.7) 1/3 (33.3) n/a n/a 1/4
(25.0)
PH-2 4/17 (23.5) 1/6 (16.7) 1/3 (33.3) n/a n/a 0/4 (0)
Symptomatic ICHd, no. (%) 1/14 (7.1) 1/4 (25.0) 0/3 (0) n/a n/a 0/4 (0) > 0.9 > 0.9
Transfer to ICU, no. (%) 69/145 (47.6) 26/52 (50.0) 11/33 (33.3) 10/15 (66.7) 0/4 (0) 10/11
(90.9)
< 0.01 0.36
Intubation, no. (%) 51/139 (36.7) 17/47 (36.2) 7/32 (21.9) 4/15 (26.7) 0/4 (0) 7/11
(63.6)
0.08 0.56
Discharge disposition, no. (%) 0.57 0.55
Home 34/136 (25.0) 11/50 (22.0) 9/29 (31.0) 4/14 (28.6) 2/4 (50.0) 5/11
(45.5)
Acute inpatient rehabilitation 18/136 (13.2) 8/50 (16.0) 3/29 (10.3) 1/14 (7.1) 1/4 (25.0) 2/11
(18.2)
Skilled nursing facility or
subacute rehabilitation
20/136 (14.7) 5/50 (10.0) 6/29 (20.7) 4/14 (28.6) 0/4 (0) 2/11
(18.2)
Long-term acute care 5/136 (3.7) 2/50 (4.0) 1/29 (3.5) 2/14 (14.3) 0/4 (0) 0/11 (0)
Other acute care facility 7/136 (5.2) 3/50 (6.0) 3/29 (10.3) 0/14 (0) 0/4 (0) 0/11 (0)
Hospice 2/136 (1.5) 1/50 (2.0) 0/29 (0) 0/14 (0) 0/4 (0) 1/11
(9.1)
Expired during hospitalization 53/139 (38.1) 20/50 (40.0) 7/29 (24.1) 3/14 (21.4) 1/4 (25.0) 1/11
(9.1)















Discharge mRS 0–2, no. (%) 35/139 (25.2) 11/51 (21.6) 11/32 (34.4) 4/14 (28.6) 3/4 (75.0) 3/10
(30.0)
0.21 0.14
In-hospital mortality, no. (%) 53/139 (38.1) 20/50 (40.0) 7/29 (24.1) 3/14 (21.4) 1/4 (25.0) 1/11
(9.1)
0.18 0.05
a Acute ischemic stroke includes suspected or radiographically-confirmed cases, and in patients with multiple possible stroke mechanisms (n = 9). Patients with
multiple stroke mechanisms were not included in the subsequent columns in order to minimize heterogeneity
b P-values indicate categorical comparisons between all stroke subtypes
c P-values indicate comparisons between cryptogenic and non-cryptogenic stroke subtypes (including strokes due to multiple possible etiologies)
d Symptomatic ICH defined as a PH-2 grade hematoma with worsening of the NIHSS by 4 or more points
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stroke. It has been described that SARS-CoV-2 infection
is linked to a prothrombotic state with elevated D-dimer
levels [24]. This finding also suggests that hypercoagula-
bility could be one of the causes underlying this high
proportion of cryptogenic strokes [25]. The high inci-
dence of intracranial occlusion (46%) and cortical
(74.4%) strokes also suggest a disproportionate number
of patients with embolic strokes who suffer from
COVID-19. These findings are in keeping with recently
published observations from a New York hospital system
[20]. Together, these observations validate the relation-
ship between a significant inflammatory and/or pro-
thrombotic state and clinically significant stroke that is
unrelated to other traditional stroke risk factors (e.g.,
cervical artery atherosclerosis or atrial fibrillation). Fur-
thermore, the higher mortality rate observed in patients
with cryptogenic stroke speaks to the severity of
COVID-19 experienced by these patients. On the other
hand, diagnostic workup for patients in this study (and
in other studies) [20, 22, 23] may not have been com-
pleted for some patients with COVID-19 in whom care
was being withdrawn or who expired soon before
workup could have been completed. This might have
confounded our observation of a high rate of crypto-
genic stroke and associated mortality, as reported in one
prior study [11].
Due to the strong relationship between cryptogenic
stroke and early mortality, we derived a simple risk score
for mortality that could serve as a useful tool in
hospitalized stroke patients with COVID-19 when mak-
ing long-term plans of care. Patients in this cohort who
met each of the 5 criteria (age, male sex, diabetes, NIHS
S 10+, cryptogenic stroke) were at an 80% chance of in-
hospital mortality, whereas those who met at least 3 cri-
teria were still more likely to die than to survive
hospitalization. However, this score is not without limi-
tations, and it certainly warrants external validation.
First, the NIHSS is not a specific indicator of stroke se-
verity in critically ill patients with COVID-19, as it can
be confounded by sedation. Second, a patient’s history of
diabetes does not reflect how well or poorly controlled
the medical condition is, and we did not evaluate the
risk of mortality based on markers of diabetic control
(e.g., hemoglobin A1c) or duration of disease. Further,
the diagnosis of a stroke as ‘cryptogenic’ may be contin-
gent upon which testing was or was not pursued to
evaluate the proximate cause of stroke in a critically ill
patient. As in previously published reports of crypto-
genic stroke in COVID-19 patients [20], patients with a
high probability of dying after a severe stroke may not
have undergone a more comprehensive workup, and
therefore could have been prematurely classified as
‘cryptogenic’. Determination of a stroke being crypto-
genic on the basis of incomplete workup due to high
probability of imminent death or pursuit of comfort
measures may have falsely contributed to its association
with in-hospital mortality. That said, as we have previ-
ously reported [7], the median delay from stroke onset
Fig. 1 Mortality rate among patients with COVID-19 and stroke according to mortality score. One point was assigned for each clinical factor up to
a total of 5 possible points: age 60 or more, male sex, NIHSS 10 or more, history of diabetes, and cryptogenic stroke
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to death was 4 days in this cohort, (IQR 1–10 days)
which suggests that echocardiographic and vascular im-
aging could have been performed in advance of
expiration.
While this study is one of the largest observational co-
horts of consecutive COVID-19 patients with cerebro-
vascular complications, it is limited by its retrospective
nature and the completeness of data elements that were
abstracted from the medical record. The imaging find-
ings were not centrally adjudicated. Selection and inter-
pretation of diagnostic tests were made at the discretion
of the treating physician, and the derivation of a simpli-
fied mortality score warrants external validation. That
said, our data reflect a large cohort of consecutive pa-
tients evaluated at many sites and reflect the diverse ex-
periences in care of patients with stroke and COVID-19.
Conclusions
Although the overall incidence rate of acute ischemic
stroke in hospitalized patients with COVID-19 is small,
there is a higher than expected proportion of patients
with cryptogenic stroke. Furthermore, patients with
cryptogenic stroke and COVID-19 are at a significantly
greater risk of early mortality when compared to patients
with COVID-19 and known, traditional stroke mecha-
nisms. The relationship between cryptogenic stroke in
COVID-19 and mortality may be driven by more severe
inflammatory or prothrombotic disease in COVID-19. A
simple 5-point score may be useful in clinical decision
making for patients at a low risk of short-term survival,
however this score requires external validation.
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